You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 3.6% | 3.7% |
Div Cover | 1.9 | 2.2 |
Op Mrgn | 24.8% | 27.0% |
ROCE | 41.8% |
Latest | Forecast | |
---|---|---|
P/E | 14.9 | 0.0 |
PEG | 0.0 | 0.5 |
Price / Revenue | 2.9 | 2.8 |
Price / Book value | 1.7 |
Latest | Forecast | |
---|---|---|
Revenue | 11,180.5% | 5.4% |
PBT | 13,140.5% | n/a |
EPS | 13,235.4% | 4.2% |
DPS | 10,491.1% | 0.2% |
Year Ending | Revenue (€m) |
Pre-tax (€m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2018-12-31 | 34,463.00 | 4,904.00 | €3.46 | 21.9 | 1.5 | 15% | €3.07 | 4.1% |
2019-12-31 | 36,126.00 | 3,077.00 | €2.33 | 38.5 | -1.2 | -33% | €3.15 | 3.5% |
2020-12-31 | 36,041.00 | 13,778.00 | €0.10 | 802.2 | -8.4 | -96% | €3.20 | 4.1% |
2021-12-31 | 37,761.00 | 7,798.00 | €0.05 | 1,765.7 | -36.1 | -49% | €0.03 | 0.0% |
2022-12-31 | 42,997.00 | 10,422.00 | €6.69 | 13.4 | 0.0 | 13,235% | €3.56 | 4.0% |
Sanofi to buy Provention Bio in $2.9bn deal Sharecast News | 13 Mar |
---|---|
AstraZeneca, Sanofi respiratory drug gets EU marketing go-ahead Sharecast News | 16 Sep |
GSK to 'vigorously defend' Zantac claims; Haleon says not a party to claims Sharecast News | 12 Aug |